18 results on '"Arora, Prerna"'
Search Results
2. Omicron subvariant BA.5 efficiently infects lung cells.
- Author
-
Hoffmann M, Wong LR, Arora P, Zhang L, Rocha C, Odle A, Nehlmeier I, Kempf A, Richter A, Halwe NJ, Schön J, Ulrich L, Hoffmann D, Beer M, Drosten C, Perlman S, and Pöhlmann S
- Subjects
- Animals, Female, Mice, Ferrets, SARS-CoV-2, Mice, Inbred BALB C, Lung, COVID-19
- Abstract
The SARS-CoV-2 Omicron subvariants BA.1 and BA.2 exhibit reduced lung cell infection relative to previously circulating SARS-CoV-2 variants, which may account for their reduced pathogenicity. However, it is unclear whether lung cell infection by BA.5, which displaced these variants, remains attenuated. Here, we show that the spike (S) protein of BA.5 exhibits increased cleavage at the S1/S2 site and drives cell-cell fusion and lung cell entry with higher efficiency than its counterparts from BA.1 and BA.2. Increased lung cell entry depends on mutation H69Δ/V70Δ and is associated with efficient replication of BA.5 in cultured lung cells. Further, BA.5 replicates in the lungs of female Balb/c mice and the nasal cavity of female ferrets with much higher efficiency than BA.1. These results suggest that BA.5 has acquired the ability to efficiently infect lung cells, a prerequisite for causing severe disease, suggesting that evolution of Omicron subvariants can result in partial loss of attenuation., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
3. Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5.
- Author
-
Hoffmann M, Arora P, Nehlmeier I, Kempf A, Cossmann A, Schulz SR, Morillas Ramos G, Manthey LA, Jäck HM, Behrens GMN, and Pöhlmann S
- Subjects
- Humans, SARS-CoV-2, Virus Internalization, Antibodies, Viral, Spike Glycoprotein, Coronavirus, Immune Evasion, Antibodies, Neutralizing, COVID-19
- Published
- 2023
- Full Text
- View/download PDF
4. Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage.
- Author
-
Arora P, Cossmann A, Schulz SR, Ramos GM, Stankov MV, Jäck HM, Behrens GMN, Pöhlmann S, and Hoffmann M
- Subjects
- Humans, SARS-CoV-2, Antibodies, Viral, COVID-19
- Abstract
Competing Interests: SP and MH do contract research on the testing of vaccinee serum samples for neutralising activity against SARS-CoV-2 for Valneva, unrelated to this work. GMNB served as an advisor for Moderna and SP served as an advisor for BioNTech, unrelated to this work. All other authors declare no competing interests. SP acknowledges funding for this project by the German Federal Ministry of Education and Research (01KI2006D), the EU project UNDINE (grant agreement number 101057100), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MWK HZI COVID-19), and the German Research Foundation (PO 716/11-1 and PO 716/14-1). H-MJ received funding from the German Federal Ministry of Education and Research (01KI2043, NaFoUniMedCovid19-COVIM 01KX2021), Bavarian State Ministry for Science and the Arts; and DFG through the research training groups RTG1660 and TRR130, the Bayerische Forschungsstiftung (Project CORAd), and the Kastner Foundation. GMNB acknowledges funding by the German Center for Infection Research (grant number 80018019238) and a European Regional Development Fund (Defeat Corona, ZW7-8515131). The funding sources had no role in study design, data collection, data analysis, data interpretation, writing of the Correspondence, or the decision to submit the manuscript for publication. We did not receive payment by a pharmaceutical company or other agency to write this Correspondence. We were not precluded from accessing data in the study and we accept responsibility to submit for publication.
- Published
- 2023
- Full Text
- View/download PDF
5. The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages.
- Author
-
Arora P, Zhang L, Nehlmeier I, Kempf A, Cossmann A, Dopfer-Jablonka A, Schulz SR, Jäck HM, Behrens GMN, Pöhlmann S, and Hoffmann M
- Subjects
- Humans, SARS-CoV-2, Antibodies, Viral, Antibodies, Neutralizing, COVID-19 prevention & control, Vaccines
- Abstract
Competing Interests: AK, IN, SP, and MH conduct contract research (testing of vaccinee sera for neutralising activity against SARS-CoV-2) for Valneva, unrelated to this work. GMNB served as an advisor for Moderna and acknowledges funding by German Center for Infection Research (grant no 80018019238) and a European Regional Development Fund (Defeat Corona, ZW78–515131). SP served as an advisor for BioNTech, unrelated to this work. SP acknowledges funding by Bundesministerium fur Bildung und Forshung (Bundesministerium fur Bildung und Forshung; 01KI2006D, 01KI20328A, 01KX2021), the EU hunam genetic and immunological determinants of the clinical manifestations of SARS-Cov-2 infection: Towards personalised medicine project (grant agreement number 101057100), the Ministry for Science and Culture of Lower Saxony (147–61031–84, MWK HZI COVID-19), and the German Research Foundation (DFG; PO716/111–, PO716/141–). H-MJ received funding from BMBF (01KI2043, NaFoUniMedCovid19-COVIM: 01KX2021), Bavarian State Ministry for Science and the Arts and DFG through the research training groups RTG1660 and TRR130, the Bayerische Forschungsstiftung (Project CORAd), and the Kastner Foundation. All other authors declare no competing interests.
- Published
- 2022
- Full Text
- View/download PDF
6. The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant.
- Author
-
Arora P, Zhang L, Rocha C, Graichen L, Nehlmeier I, Kempf A, Cossmann A, Ramos GM, Baier E, Tampe B, Moerer O, Dickel S, Winkler MS, Behrens GMN, Pöhlmann S, and Hoffmann M
- Subjects
- Humans, SARS-CoV-2 genetics, Viral Envelope Proteins genetics, BNT162 Vaccine, Membrane Glycoproteins metabolism, Spike Glycoprotein, Coronavirus genetics, COVID-19
- Abstract
Recently, a recombinant SARS-CoV-2 lineage, XD, emerged that harbors a spike gene that is largely derived from the Omicron variant BA.1 in the genetic background of the Delta variant. This finding raised concerns that the recombinant virus might exhibit altered biological properties as compared to the parental viruses and might pose an elevated threat to human health. Here, using pseudotyped particles, we show that ACE2 binding and cell tropism of XD mimics that of BA.1. Further, XD and BA.1 displayed comparable sensitivity to neutralization by antibodies induced upon vaccination with BNT162b2/Comirnaty (BNT) or BNT vaccination followed by breakthrough infection. Our findings reveal important biological commonalities between XD and Omicron BA.1 host cell entry and its inhibition by antibodies.
- Published
- 2022
- Full Text
- View/download PDF
7. SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications.
- Author
-
Schlör A, Hirschberg S, Amor GB, Meister TL, Arora P, Pöhlmann S, Hoffmann M, Pfaender S, Eddin OK, Kamhieh-Milz J, and Hanack K
- Subjects
- Antibodies, Viral, COVID-19 Testing, Humans, Immunoglobulin G, Immunoglobulin Heavy Chains genetics, Pandemics, SARS-CoV-2, COVID-19 diagnosis, Spike Glycoprotein, Coronavirus
- Abstract
Introduction: The ongoing COVID-19 pandemic situation caused by SARS-CoV-2 and variants of concern such as B.1.617.2 (Delta) and recently, B.1.1.529 (Omicron) is posing multiple challenges to humanity. The rapid evolution of the virus requires adaptation of diagnostic and therapeutic applications., Objectives: In this study, we describe camelid heavy-chain-only antibodies (hcAb) as useful tools for novel in vitro diagnostic assays and for therapeutic applications due to their neutralizing capacity., Methods: Five antibody candidates were selected out of a naïve camelid library by phage display and expressed as full length IgG2 antibodies. The antibodies were characterized by Western blot, enzyme-linked immunosorbent assays, surface plasmon resonance with regard to their specificity to the recombinant SARS-CoV-2 Spike protein and to SARS-CoV-2 virus-like particles. Neutralization assays were performed with authentic SARS-CoV-2 and pseudotyped viruses (wildtype and Omicron)., Results: All antibodies efficiently detect recombinant SARS-CoV-2 Spike protein and SARS-CoV-2 virus-like particles in different ELISA setups. The best combination was shown with hcAb B10 as catcher antibody and HRP-conjugated hcAb A7.2 as the detection antibody. Further, four out of five antibodies potently neutralized authentic wildtype SARS-CoV-2 and particles pseudotyped with the SARS-CoV-2 Spike proteins of the wildtype and Omicron variant, sublineage BA.1 at concentrations between 0.1 and 0.35 ng/mL (ND50)., Conclusion: Collectively, we report novel camelid hcAbs suitable for diagnostics and potential therapy., Competing Interests: KH is shareholder and CEO of new/era/mabs GmbH. AS is employed at new/era/mabs. OE is associated with Wimedko GmbH. GBA is employed at Wimedko GmbH. JK-M was employed at Wimedko GmbH. KH and AS are inventors of the European patent application No. EP21212985.2. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Schlör, Hirschberg, Amor, Meister, Arora, Pöhlmann, Hoffmann, Pfaender, Eddin, Kamhieh-Milz and Hanack.)
- Published
- 2022
- Full Text
- View/download PDF
8. Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2.
- Author
-
Arora P, Kempf A, Nehlmeier I, Graichen L, Schulz S, Cossmann A, Dopfer-Jablonka A, Winkler MS, Jäck HM, Behrens GMN, Pöhlmann S, and Hoffmann M
- Subjects
- Angiotensin-Converting Enzyme 2, Binding Sites, Humans, Mutation, Protein Binding, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus metabolism, COVID-19, SARS-CoV-2
- Published
- 2022
- Full Text
- View/download PDF
9. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.
- Author
-
Hoffmann M, Sidarovich A, Arora P, Krüger N, Nehlmeier I, Kempf A, Graichen L, Winkler MS, Niemeyer D, Goffinet C, Drosten C, Schulz S, Jäck HM, and Pöhlmann S
- Subjects
- Angiotensin-Converting Enzyme 2, Animals, Antibodies, Viral, Cell Line, Chlorocebus aethiops, Humans, Mutation, Protein Binding, Receptors, Virus metabolism, Spike Glycoprotein, Coronavirus metabolism, Vero Cells, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Neutralizing pharmacology, COVID-19 therapy, SARS-CoV-2 physiology, Virus Internalization
- Abstract
SARS-CoV-2 variants of concern (VOC) acquired mutations in the spike (S) protein, including E484K, that confer resistance to neutralizing antibodies. However, it is incompletely understood how these mutations impact viral entry into host cells. Here, we analyzed how mutations at position 484 that have been detected in COVID-19 patients impact cell entry and antibody-mediated neutralization. We report that mutation E484D markedly increased SARS-CoV-2 S-driven entry into the hepatoma cell line Huh-7 and the lung cell NCI-H1299 without augmenting ACE2 binding. Notably, mutation E484D largely rescued Huh-7 but not Vero cell entry from blockade by the neutralizing antibody Imdevimab and rendered Huh-7 cell entry ACE2-independent. These results suggest that the naturally occurring mutation E484D allows SARS-CoV-2 to employ an ACE2-independent mechanism for entry that is largely insensitive against Imdevimab, an antibody employed for COVID-19 therapy. IMPORTANCE The interaction of the SARS-CoV-2 spike protein (S) with the cellular receptor ACE2 is considered essential for infection and constitutes the key target for antibodies induced upon infection and vaccination. Here, using a surrogate system for viral entry, we provide evidence that a naturally occurring mutation can liberate SARS-CoV-2 from ACE2-dependence and that ACE2-independent entry may protect the virus from neutralization by an antibody used for COVID-19 therapy.
- Published
- 2022
- Full Text
- View/download PDF
10. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3.
- Author
-
Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, Cossmann A, Manger B, Baier E, Tampe B, Moerer O, Dickel S, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Winkler MS, Pöhlmann S, and Hoffmann M
- Subjects
- Humans, Mutation, Spike Glycoprotein, Coronavirus genetics, COVID-19, SARS-CoV-2
- Abstract
Competing Interests: SP acknowledges funding from Bundesministerium für Bildung und Forschung (BMBF; grant numbers 01KI2006D, 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (grant numbers 14-76103-184, MWK HZI COVID-19), and the German Research Foundation (DFG; grant numbers PO 716/11-1, PO 716/14-1). MSW received unrestricted funding from Sartorius, Lung research. H-MJ received funding from BMBF (grant numbers 01KI2043, NaFoUniMedCovid19-COVIM 01KX2021), Bavarian State Ministry for Science and the Arts, and DFG through the research training groups RTG1660 and TRR130, the Bayerische Forschungsstiftung (Project CORAd), and the Kastner Foundation. GMNB acknowledges funding from the German Center for Infection Research (grant number 80018019238) and a European Regional Development Fund (Defeat Corona, grant number ZW7-8515131, together with AD-J). All other authors declare no competing interests.
- Published
- 2022
- Full Text
- View/download PDF
11. SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination.
- Author
-
Arora P, Kempf A, Nehlmeier I, Graichen L, Winkler MS, Lier M, Schulz S, Jäck HM, Cossmann A, Stankov MV, Behrens GMN, Pöhlmann S, and Hoffmann M
- Subjects
- Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, Humans, Spike Glycoprotein, Coronavirus, Vaccination, COVID-19, SARS-CoV-2
- Abstract
Rapid spread of SARS-CoV-2 variants C.1.2 and B.1.621 (Mu variant) in Africa and the Americas, respectively, as well as a high number of mutations in the viral spike proteins raised concerns that these variants might pose an elevated threat to human health. Here, we show that C.1.2 and B.1.621 spike proteins mediate increased entry into certain cell lines but do not exhibit increased ACE2 binding. Further, we demonstrate that C.1.2 and B.1.621 are resistant to neutralization by bamlanivimab but remain sensitive to inhibition by antibody cocktails used for COVID-19 therapy. Finally, we show that C.1.2 and B.1.621 partially escape neutralization by antibodies induced upon infection and vaccination, with escape of vaccine-induced antibodies being as potent as that measured for B.1.351 (Beta variant), which is known to be highly neutralization resistant. Collectively, C.1.2 and B.1.621 partially evade control by vaccine-induced antibodies, suggesting that close monitoring of these variants is warranted., Competing Interests: Declaration of interests M.S.W. received unrestricted funding for independent research projects from Sartorius., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2.
- Author
-
Arora P, Kempf A, Nehlmeier I, Graichen L, Winkler MS, Lier M, Schulz S, Jäck HM, Pöhlmann S, and Hoffmann M
- Subjects
- Humans, Mutation immunology, Neutralization Tests methods, Spike Glycoprotein, Coronavirus immunology, Virus Internalization, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, COVID-19 immunology, SARS-CoV-2 immunology
- Abstract
Since the beginning of the COVID-19 pandemic, multiple SARS-CoV-2 variants have emerged. While some variants spread only locally, others, referred to as variants of concern, disseminated globally and became drivers of the pandemic. All SARS-CoV-2 variants harbor mutations relative to the virus circulating early in the pandemic, and mutations in the viral spike (S) protein are considered of particular relevance since the S protein mediates host cell entry and constitutes the key target of the neutralizing antibody response. As a consequence, mutations in the S protein may increase SARS-CoV-2 infectivity and enable its evasion of neutralizing antibodies. Furthermore, mutations in the S protein can modulate viral transmissibility and pathogenicity., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
13. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance.
- Author
-
Arora P, Kempf A, Nehlmeier I, Graichen L, Sidarovich A, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S, and Hoffmann M
- Subjects
- Animals, COVID-19 Vaccines, Chlorocebus aethiops, Databases, Genetic, Humans, Mutation, Spike Glycoprotein, Coronavirus immunology, T-Lymphocytes immunology, T-Lymphocytes virology, Vero Cells, Vietnam, Antibodies, Neutralizing chemistry, COVID-19 virology, Neutralization Tests, SARS-CoV-2 genetics, SARS-CoV-2 physiology
- Published
- 2021
- Full Text
- View/download PDF
14. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination.
- Author
-
Arora P, Sidarovich A, Krüger N, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S, and Hoffmann M
- Subjects
- Adult, Antibodies, Monoclonal immunology, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, BNT162 Vaccine, COVID-19 metabolism, COVID-19 therapy, COVID-19 Vaccines immunology, Cell Fusion, Cell Line, Female, HEK293 Cells, Humans, Immune Evasion physiology, Immunization, Passive methods, Lung pathology, Lung virology, Male, Middle Aged, Neutralization Tests, SARS-CoV-2 metabolism, SARS-CoV-2 pathogenicity, Spike Glycoprotein, Coronavirus immunology, Vaccination methods, COVID-19 Serotherapy, COVID-19 immunology, Immune Evasion immunology, SARS-CoV-2 immunology
- Abstract
The Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), B.1.617.2, emerged in India and has spread to over 80 countries. B.1.617.2 replaced B.1.1.7 as the dominant virus in the United Kingdom, resulting in a steep increase in new infections, and a similar development is expected for other countries. Effective countermeasures require information on susceptibility of B.1.617.2 to control by antibodies elicited by vaccines and used for coronavirus disease 2019 (COVID-19) therapy. We show, using pseudotyping, that B.1.617.2 evades control by antibodies induced upon infection and BNT162b2 vaccination, although to a lesser extent as compared to B.1.351. We find that B.1.617.2 is resistant against bamlanivimab, a monoclonal antibody with emergency use authorization for COVID-19 therapy. Finally, we show increased Calu-3 lung cell entry and enhanced cell-to-cell fusion of B.1.617.2, which may contribute to augmented transmissibility and pathogenicity of this variant. These results identify B.1.617.2 as an immune evasion variant with increased capacity to enter and fuse lung cells., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
15. Mutation D614G increases SARS-CoV-2 transmission.
- Author
-
Arora P, Pöhlmann S, and Hoffmann M
- Subjects
- Humans, Mutation, Spike Glycoprotein, Coronavirus genetics, COVID-19, SARS-CoV-2
- Published
- 2021
- Full Text
- View/download PDF
16. SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications
- Author
-
Schlör, Anja, Hirschberg, Stefan, Ben Amor, Ghada, Meister, Toni Luise, Arora, Prerna, Pöhlmann, Stefan, Hoffmann, Markus, Pfänder, Stephanie, Eddin, Omar Kamal, Kamhieh-Milz, Julian, Hanack, Katja, Drexler, Ingo (Prof. Dr. med.), Alpan, Oral (Dr. med.), and De Gaspari, Elizabeth (PhD)
- Subjects
SARS-CoV-2 ,Immunology ,COVID-19 ,Antibodies, Viral ,Extern ,COVID-19 Testing ,Immunoglobulin G ,Spike Glycoprotein, Coronavirus ,Immunology and Allergy ,Humans ,ddc:610 ,Immunoglobulin Heavy Chains ,610 Medizin und Gesundheit ,Pandemics ,Institut für Biochemie und Biologie - Abstract
Introduction: The ongoing COVID-19 pandemic situation caused by SARS-CoV-2 and variants of concern such as B.1.617.2 (Delta) and recently, B.1.1.529 (Omicron) is posing multiple challenges to humanity. The rapid evolution of the virus requires adaptation of diagnostic and therapeutic applications. Objectives: In this study, we describe camelid heavy-chain-only antibodies (hcAb) as useful tools for novel in vitro diagnostic assays and for therapeutic applications due to their neutralizing capacity. Methods: Five antibody candidates were selected out of a naïve camelid library by phage display and expressed as full length IgG2 antibodies. The antibodies were characterized by Western blot, enzyme-linked immunosorbent assays, surface plasmon resonance with regard to their specificity to the recombinant SARS-CoV-2 Spike protein and to SARS-CoV-2 virus-like particles. Neutralization assays were performed with authentic SARS-CoV-2 and pseudotyped viruses (wildtype and Omicron). Results: All antibodies efficiently detect recombinant SARS-CoV-2 Spike protein and SARS-CoV-2 virus-like particles in different ELISA setups. The best combination was shown with hcAb B10 as catcher antibody and HRP-conjugated hcAb A7.2 as the detection antibody. Further, four out of five antibodies potently neutralized authentic wildtype SARS-CoV-2 and particles pseudotyped with the SARS-CoV-2 Spike proteins of the wildtype and Omicron variant, sublineage BA.1 at concentrations between 0.1 and 0.35 ng/mL (ND50). Conclusion: Collectively, we report novel camelid hcAbs suitable for diagnostics and potential therapy., Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe; 1280
- Published
- 2022
- Full Text
- View/download PDF
17. Understanding Omicron: Transmissibility, immune evasion and antiviral intervention.
- Author
-
Hoffmann, Markus, Arora, Prerna, and Pöhlmann, Stefan
- Subjects
- *
SARS-CoV-2 Omicron variant , *SARS-CoV-2 , *IMMUNOGLOBULINS , *MONOCLONAL antibodies , *SARS-CoV-2 Delta variant , *COVID-19 - Abstract
WHICH ANTIVIRAL TREATMENT OPTIONS ARE SUITABLE FOR THERAPY OF PATIENTS INFECTED WITH THE OMIC... Treatment with recombinant monoclonal antibodies (mAbs) that neutralize SARS-CoV-2 can reduce the risk for severe disease. In contrast, neutralization of the Omicron variant is dramatically reduced,1 indicating that immunity following infection by previously circulating SARS-CoV-2 variants provides little to no protection against the Omicron variant. Keywords: antibody; omicron; SARS-CoV-2; spike EN antibody omicron SARS-CoV-2 spike 1 3 3 05/31/22 20220501 NES 220501 The severe acute respiratory syndrome coronavirus 2 Omicron variant (B.1.1.529) swept the globe with breathtaking speed, rapidly displacing the Delta variant and causing record numbers of new infections. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
18. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
- Author
-
Hoffmann, Markus, Arora, Prerna, Groß, Rüdiger, Seidel, Alina, Hörnich, Bojan F., Hahn, Alexander S., Krüger, Nadine, Graichen, Luise, Hofmann-Winkler, Heike, Kempf, Amy, Winkler, Martin S., Schulz, Sebastian, Jäck, Hans-Martin, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Müller, Martin, Kleger, Alexander, Münch, Jan, and Pöhlmann, Stefan
- Subjects
- *
SARS-CoV-2 , *CONVALESCENT plasma , *COVID-19 pandemic , *COVID-19 treatment , *COVID-19 - Abstract
The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, the recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of all variants into human cells is susceptible to blockade by the entry inhibitors soluble ACE2, Camostat, EK-1, and EK-1-C4. In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. Moreover, entry of these variants was less efficiently inhibited by plasma from convalescent COVID-19 patients and sera from BNT162b2-vaccinated individuals. These results suggest that SARS-CoV-2 may escape neutralizing antibody responses, which has important implications for efforts to contain the pandemic. [Display omitted] • B.1.1.7, B.1.351, and P.1 do not show augmented host cell entry • Entry inhibitors under clinical evaluation block all variants • B.1.351 and P.1 can escape from therapeutic antibodies • B.1.351 and P.1 evade antibodies induced by infection and vaccination Comparison of the SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 shows that inhibitors under clinical evaluation are still effective in blocking entry, though the B.1.351 and P.1 variants evade antibody responses induced upon infection as well as vaccination and evade certain therapeutic antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.